Attached files
| file | filename |
|---|---|
| 10-K - 10-K - CALLISTO PHARMACEUTICALS INC | a2197674z10-k.htm |
| EX-21 - EXHIBIT 21 - CALLISTO PHARMACEUTICALS INC | a2197674zex-21.htm |
| EX-32.2 - EXHIBIT 32.2 - CALLISTO PHARMACEUTICALS INC | a2197674zex-32_2.htm |
| EX-31.2 - EXHIBIT 31.2 - CALLISTO PHARMACEUTICALS INC | a2197674zex-31_2.htm |
| EX-32.1 - EXHIBIT 32.1 - CALLISTO PHARMACEUTICALS INC | a2197674zex-32_1.htm |
| EX-31.1 - EXHIBIT 31.1 - CALLISTO PHARMACEUTICALS INC | a2197674zex-31_1.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
Callisto
Pharmaceuticals, Inc.
New York, New York
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-119648 and 333-130716) of Callisto Pharmaceuticals, Inc. and Subsidiaries (a development stage company) (the "Company") of our report dated March 31, 2010, relating to the consolidated financial statements which appear in this Form 10-K. Our report on the consolidated financial statements contains an explanatory paragraph regarding the Company's ability to continue as a going concern.
/s/ BDO Seidman, LLP
New
York, New York
March 31, 2010